Jim Bergthold M.D. Internal Medicine Physician & Principal Investigator at Summit Research Network talked with Helen today about the incidence of Multiple Sclerosis in Oregon, how it's treated and how people can be part of a new study at Summit Research Network.
• Summit Research Network is conducting a study with Gilenya.  75% of patients who are currently on another DMT will be switched to Gilenya.  The others will stay on their current DMT for 6 mos.  At the end of the 6 mos, those that were not in the Gilenya group, will be given the opportunity try Gilenya for 3 mos. 
• Throughout the study, Summit Research will work with the patient's Neurologist to keep them informed of how the patient is doing.  At the end of the study, care is transferred back to the current Neurologist and we can work with the Neurologist to continue Gilenya if the patient and Neurologist wishes to continue on that path.
 
To learn more about this research study you can call the office at (503) 228-CARE (2273) or visit us at SummitPortland.com
 

They will also be hosting an informal lunch session with Dr. Bergthold that is open to the public to learn more about this research study. It will be held at the Montgomery Park building on Wednesday , June 15 from 11:00a.m.-12:00p.  A light lunch will be served.  Call (503) 228-CARE to reserve your spot.